🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

186 results for “Air” Clear

  1. CT1812

    COGNITION THERAPEUTICS INC

    Cognitive Impairment

    phase 1 small molecule completed

    1 trial

  2. Dabigatran

    BRIGHT MINDS BIOSCIENCES INC.

    Mild Cognitive Impairment

    phase 1 small molecule terminated

    1 trial

  3. Dazucorilant

    CORCEPT THERAPEUTICS INC

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  4. Deflazacort

    PTC THERAPEUTICS, INC.

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  5. Deflazacort

    PTC THERAPEUTICS, INC.

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  6. EDG-7500

    Edgewise Therapeutics

    Hepatic Impairment (HI)

    phase 1 small molecule active

    1 trial

  7. EDG-7500

    Edgewise Therapeutics

    Renal Impairments

    phase 1 small molecule completed

    1 trial

  8. ELX-02

    Eloxx Pharmaceuticals

    Impaired Renal Function

    phase 1 small molecule completed

    1 trial

  9. Effect of Renal Impairment on Enpatoran Pharmacokinetics

    Merck Sharp and Dohme

    Healthy volunteers and patients with renal impairment; Intended indication: autoimmune diseases; systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), as well as dermatomyositis (DM) and polymyositis (PM).

    phase 1 other active

    1 trial

  10. Entinostat

    Syndax Pharmaceuticals Inc

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  11. Fazirsiran

    Takeda Pharmaceuticals International AG

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  12. First-in-Human Study of RO7812653

    Roche Registration Limited

    Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia)

    phase 1 other active

    1 trial

  13. GC4419

    Galera Therapeutics

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  14. GLPG0634

    Lakefront Biotherapeutics NV

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  15. GS-5245 tablets 175 mg, GS-5245 tablets 350 mg

    Gilead Sciences International Limited

    Renal Impairment

    phase 1 small molecule active

    1 trial

  16. HSK3486

    First Tracks Biotherapeutics

    Chronic Renal Impairment

    phase 1 small molecule completed

    1 trial

  17. Hydrocodone Bitartrate extended-release tablet

    Teva Pharma GmbH

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  18. Hydrocodone bitartrate extended-release tablet

    Teva Pharma GmbH

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  19. ISIS 681257

    IONIS PHARMACEUTICALS INC

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  20. IXP

    Vertex Pharmaceuticals (Ireland) Limited

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  21. Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.

    Novo Nordisk A/S

    Obesity and Diabetes mellitus Typ 2

    phase 1 other active

    1 trial

  22. MBX 2109

    MBX Biosciences

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  23. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  24. Medium THC

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Impairment

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources